Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: Differentiation among glycoprotein IIb/IIIa antagonists

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 4, 2000, Pages 1162-1167

  Mousa, Shaker A ^a   Khurana, Sandeep ^b   Forsythe, Mark S ^a  

^a DUPONT COMPANY   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Binding kinetics; Integrins; Platelet glycoprotein IIb IIIa antagonists; Thromboelastography; Tissue factor

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; INTEGRIN; ORBOFIBAN; ROXIFIBAN; SIBRAFIBAN; THROMBOPLASTIN;

ARTICLE; BLOOD CLOT RETRACTION; CELL DEATH; DRUG EFFECT; DRUG EFFICACY; FIBRIN CLOT; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SHEAR STRESS; THROMBOCYTE ACTIVATION; THROMBOELASTOGRAPHY; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0034127789     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.4.1162     Document Type: Article

References (33)

1. Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol. 1985;5:175B-184B.
2. Hamm CW, Bliefield W, Kupper W, Lorenz RL, Weber PC, Wober W. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol. 1987;10:998-1004.
3. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 1989;80:198-205.
4. Davies MJ, Thomas AC. Plaque fissuring-the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J. 1985;53:363-373.
5. Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Hematol Oncol Clin North Am. 1990;4:1-26.
6. Pytela R, Pierschbacher MS, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of RGD specific adhesion receptors. Science. 1986;231:1559-1562.
7. Andrieux A, Hudry-Clergion G, Ryckewaert J-J, Chapel A, Ginsberg MH, Plow EF, Margueire G. Amino acid sequences in fibrinogen mediating its interaction with its platelet receptor, GPIIb/IIIa. J Biol Chem. 1989;264:9258-9264.
8. Topol EJ, Plow EF. Clinical trials of platelet receptor inhibitors. Thromb Haemost. 1993;70:94-98.
9. Nicholson NS, Panzer-Knodle SG, Haas NF, Taite BB, Szalony JA, Page JD, Feigen LP, Lansky DM, Salyers AK. Assessment of platelet function assays. Am Heart J. 1998;135(pt 2, suppl)S170-S178.
10. Cohen K, Gerrard JM, White JG. Ultrastructure of clots during isometric contraction. J Cell Biol. 1982;93:775-483.
11. Brasten JV, Jerome WG, Hantgan RR. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface. Blood. 1994; 83:982-990.
12. Hantgan RR, Taylor RG, Lewis JC. Platelets interact with fibrin only after activation. Blood. 1985;65:1299-1308.
13. Reid TJ, Greilich PE, Carr ME, Alving BM. Quantitative clot retraction: a method assessing the function of fresh and stored platelets and GPIIb/IIIa receptors. Blood. 1994;84:1839-1847.
14. Mousa SA, Forsythe M, Lorelli W, Bozarth J, Xue C-B, Wityak J, Sielecki TM, Olson R, Degrado W, Kapil R, Hussain M, Wexler R, Thoolen M, Reilly TM. Novel nonpeptide antiplatelet GPIIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity. Coron Artery Dis. 1996;7:767-774
15. Hartert H. Blutgerinnungstudien mit der Thromboelastograpie, einem ueuen Untersuchungsverfahren. Klin Wochenschr. 1948;26:577-583.
16. Essell JH, Martin TJ, Salinas J, Thompson JM, Smith VC. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1993;7:410-415.
17. Muller N, Popov-Cenic S, Buttner W, Kladetsky RG, Egil H. Studies of fibrinolytic and coagulation factors during open heart surgery, II: post-operative tendency and changes in the coagulation system. Thromb Res. 1975;7:589-598.
18. Spiess BD, Tuman KJ, McCarthy RJ, DeLaria GA, Schillo R, Ivankovich AD. Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathies. J Clin Monit. 1987;3:25-30.
19. Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth. 1995; 9:168-173.
20. The EPIC Investigators. Use of a monoclonal antibody directed against the glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
21. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody c7E3 after thrombolytic therapy: results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol. 1993;22:381-389.
22. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintal D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet GPIIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343: 881-886.
23. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction: platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms. N Engl J Med. 1998;338:1488-1497.
24. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mee CP, Califf RM, Topol EJ. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker, integrilin in elective coronary intervention: IMPACT investigators. Circulation. 1995;91: 2151-2157.
25. Théroux P, Kouz S, Knudtson ML, et al. A randomized double-blind controlled trial with the non-peptide platelet GPIIb/IIIa antagonist RO 44-9883 in unstable angina. Circulation. 1994;90(suppl I):I-232. Abstract.
26. Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove CS, DeFranco AC, Ellis SG, Moliterno DJ, Raymond RE, Sutton JM, Topol EJ. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation. 1997;96:76-81.
27. Muller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Profound and sustained inhibition of platelet aggregation by fradafiban, nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men. Circulation. 1997;96:1130-1138.
28. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial: thrombolysis in myocardial infarction. Circulation. 1998;97:340-349.
29. Harrington RA, Graffagnino C, Armstrong PW, Joseph D, Card TL, et al. Dose-finding and tolerability of a new oral platelet GPIIb/IIIa inhibitor, SB 214857, in patients with coronary artery and cerebrovascular disease: the APLAUD results. Circulation. 1998;98(suppl I):I-251. Abstract.
30. Mousa SA, Topol EJ. Novel antiplatelet therapies: recent advances in the development of platelet GPIIb/IIIa receptor antagonists. In: Serruys PW, Holmes D, eds. Current Review of Interventional Cardiology. 3rd ed. Philadelphia, Pa: Current Medicine; 1997;13:114-129.
31. Mousa SA, Bozarth J, Lorelli W, Forsythe M, Thoolen M, Slee A, Reilly T, Friedman P. Discovery of novel orally active non-peptide platelet GPIIb/IIIa receptor antagonist, DMP754: comparative platelet binding profiles with c7E3. J Pharmacol Exp Ther. 1998;286:1277-1284.
32. Mousa SA, Wityak J. Orally active isoxazoline GPIIb/IIIa antagonists. Cardiovasc Drug Rev. 1998;16:48-61.
33. Greilich PE, Alving BM, Longnecker D, Carr ME Jr, Whitten CW, Chang AS, Reid TJ. Near-site monitoring of the antiplatelet drug abciximab using the Hemodyne analyzer and modified thrombelastograph. J Cardiothorac Vasc Anesth. 1999;13:58-64.